Mankind Pharma (MANKIND) Aperçu de l'action
Mankind Pharma Limited développe, fabrique et commercialise des formulations pharmaceutiques et des produits de santé grand public, principalement en Inde et à l'étranger. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 3/6 |
| Performances passées | 2/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour MANKIND à partir de nos contrôles de risques.
MANKIND Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mankind Pharma Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹2,483.00 |
| Plus haut sur 52 semaines | ₹2,674.00 |
| Plus bas sur 52 semaines | ₹1,909.70 |
| Bêta | 0.45 |
| Variation sur 1 mois | -1.80% |
| Variation sur 3 mois | 7.05% |
| Variation sur 1 an | -5.55% |
| Variation sur 3 ans | 37.68% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 74.58% |
Nouvelles et mises à jour récentes
Article d’analyse • Aug 02
Mankind Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Mankind Pharma Limited ( NSE:MANKIND ) recently reported its quarterly numbers. It looks like a...
Mise à jour du récit • Aug 01
MANKIND: Subsidiary Moves And Margin Outlook Will Support Future Re Rating
Analysts have lifted their price target on Mankind Pharma from ₹3,100 to ₹3,220, citing updated assumptions that include a revised profit margin outlook and a slightly different forward P/E framework. What’s in the News for Mankind Pharma Mankind Pharma has scheduled a board meeting on July 30, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Article d’analyse • Jul 13
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results
The yearly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to revisit...Recent updates
Article d’analyse • Aug 02
Mankind Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Mankind Pharma Limited ( NSE:MANKIND ) recently reported its quarterly numbers. It looks like a...Mise à jour du récit • Aug 01
MANKIND: Subsidiary Moves And Margin Outlook Will Support Future Re Rating
Analysts have lifted their price target on Mankind Pharma from ₹3,100 to ₹3,220, citing updated assumptions that include a revised profit margin outlook and a slightly different forward P/E framework. What’s in the News for Mankind Pharma Mankind Pharma has scheduled a board meeting on July 30, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Article d’analyse • Jul 13
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Yearly Results
The yearly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to revisit...
Mise à jour du récit • Jun 29
MANKIND: Higher Growth Assumptions Will Be Offset By Weaker Profitability
Analysts have lifted their fair value estimate for Mankind Pharma from ₹1,990 to about ₹2,062, reflecting updated assumptions that combine higher revenue growth expectations with slightly lower profit margin forecasts and a modestly reduced future P/E multiple. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider several corporate actions.Mise à jour du récit • Jun 15
MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating
Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.
Mise à jour du récit • Jun 01
MANKIND: Higher Future Multiple And Subsidiary Exit Will Support Further Upside
Analysts have raised their fair value estimate for Mankind Pharma from ₹2,515.74 to ₹2,653.40, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, at 15:10 IST to consider standalone and consolidated audited financial results for the quarter and year ended March 31, 2026; review security cover for existing non convertible debentures after the redemption of ₹1,250 crore of NCDs on April 16, 2026; consider management changes; and evaluate an additional investment in its subsidiary, Mankind Medicare Private Limited (source: company board agenda).Article d’analyse • May 22
Analysts Have Made A Financial Statement On Mankind Pharma Limited's (NSE:MANKIND) Yearly Report
It's been a good week for Mankind Pharma Limited ( NSE:MANKIND ) shareholders, because the company has just released...Mise à jour du récit • May 05
MANKIND: Subsidiary Exit And Firm Margins Will Support Further Upside
Mankind Pharma's analyst price target has been adjusted slightly higher from ₹2,506.53 to ₹2,515.74 as analysts update their assumptions around revenue growth, profit margin and forward P/E expectations. What's in the News The board is scheduled to meet on April 13, 2026, at 15:00 Indian Standard Time to review corporate matters, including the subsidiary structure (company filing).Mise à jour du récit • Apr 20
MANKIND: Subsidiary Closure Decision Will Support Future Re Rating Potential
Analysts have made a slight trim to the price target for Mankind Pharma, with fair value moving from ₹3,100.00 to about ₹3,085.68 as they refresh assumptions around revenue growth, profit margins, and future P/E levels. What's in the News The board plans to meet on Apr 13, 2026, at 15:00 Indian Standard Time to review and approve the closure of Mankind Pharma Lanka Private Limited, the wholly owned subsidiary in Sri Lanka, following changes in local regulatory requirements (Key Developments).Mise à jour du récit • Apr 06
MANKIND: Upcoming Results And Solid Margins Will Support Further Upside
Analysts have cut their price target on Mankind Pharma by ₹30 to reflect slightly lower assumptions for revenue growth, profit margins and future P/E multiples, resulting in a modest reset in fair value expectations. What's in the News A board meeting is scheduled on Feb 3, 2026 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Mise à jour du récit • Mar 22
MANKIND: Upcoming Board Review And Steady Assumptions Will Support Bullish Re Rating
Analysts have kept Mankind Pharma's fair value estimate unchanged at ₹3,100 per share, citing slightly higher assumptions for revenue growth at 14.04% and profit margin at 21.31%, along with a marginally lower future P/E of 41.44x. What's in the News Board meeting scheduled for Feb 03, 2026 at 15:00 IST to review and approve unaudited standalone financial results for the quarter ended Dec 31, 2025, along with the Limited Review Report (company filing).Mise à jour du récit • Mar 08
MANKIND: Upcoming Results And Firmer Margins Will Support Bullish Re-Rating
Analysts have slightly reduced their fair value estimate for Mankind Pharma to ₹3,100 from ₹3,110, reflecting updated assumptions around modestly different revenue growth, margins, and future P/E expectations. What's in the News A board meeting is scheduled on February 3, 2026, at 15:00 Indian Standard Time to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report (Key Developments).Mise à jour du récit • Feb 22
MANKIND: Upcoming Results Will Support Further Upside Despite Modest Assumption Cuts
Analysts have trimmed their price target for Mankind Pharma from about ₹2,631 to about ₹2,537. This reflects slightly lower assumptions for revenue growth, profit margins and future P/E multiples, alongside a modestly reduced discount rate.Mise à jour du récit • Feb 08
MANKIND: Fair Value Outlook Will Reflect Lower Growth And Higher Margins
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹2,150 to ₹1,990, citing updates to revenue growth, profit margin and assumed future P/E levels in their revised models. What's in the News Mankind Pharma has scheduled a board meeting on Feb 03, 2026, at 15:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Mise à jour du récit • Jan 24
MANKIND: Firmer Margins And Upcoming Results Will Support Future Bullish Re-Rating
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹3,260 to ₹3,110, citing slightly softer revenue growth expectations, partly offset by firmer profit margin and P/E assumptions. What's in the News Board meeting scheduled on Feb 03, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Mise à jour du récit • Jan 10
MANKIND: Rising Margins And Upcoming Results Will Support Further Upside
Analysts have trimmed their price target for Mankind Pharma from ₹2,699 to ₹2,631, citing updated assumptions that reflect slightly different expectations for revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on Nov 06, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Article d’analyse • Dec 14
Does Mankind Pharma (NSE:MANKIND) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Dec 14
MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating
Narrative Update Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook. What's in the News Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) Valuation Changes Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.Mise à jour du récit • Nov 27
MANKIND: Rising Margins And Upcoming Results Will Drive Further Upside
Analysts have slightly reduced their fair value estimate for Mankind Pharma from ₹2,725.59 to ₹2,699.12. They cite minor adjustments in projected revenue growth and profit margins as influencing factors.Article d’analyse • Nov 09
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Second-Quarter Results
Last week, you might have seen that Mankind Pharma Limited ( NSE:MANKIND ) released its quarterly result to the market...Mise à jour du récit • Nov 08
MANKIND: Expansion Into Russia And Rising Margins Will Drive Upside
Analysts have revised the fair value estimate for Mankind Pharma down from ₹2,799.65 to ₹2,725.59. This revision reflects slightly lower revenue growth expectations, partially offset by stronger profit margins and a marginally higher discount rate.Article d’analyse • Nov 08
Mankind Pharma Limited's (NSE:MANKIND) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 53.4x Mankind Pharma Limited ( NSE:MANKIND ) may be sending very bearish...Mise à jour du récit • Sep 05
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
With little change in both net profit margin and future P/E, there has been no effective revision to Mankind Pharma's consensus analyst price target, which remains at ₹2800. What's in the News Incorporated wholly owned subsidiary in Russia under the name Mankind Pharma LLC.
Nouveau récit • Nov 12
Decisive Acquisition And Global Expansion Set To Revitalize Revenue Growth And Profitability
Strategic acquisitions and specialization in high-entry barrier segments are expected to enhance revenue growth and margins through synergies and R&D leverage.Rendement pour les actionnaires
| MANKIND | IN Pharmaceuticals | IN Marché | |
|---|---|---|---|
| 7D | -2.7% | 2.3% | 2.0% |
| 1Y | -5.5% | 16.0% | 3.6% |
Rendement vs Industrie: MANKIND a sous-performé le secteur Indian Pharmaceuticals qui a rapporté 16 % au cours de l'année écoulée.
Rendement vs marché: MANKIND a sous-performé le marché Indian qui a rapporté 3.6 % au cours de l'année écoulée.
Volatilité des prix
| MANKIND volatility | |
|---|---|
| MANKIND Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Cours de l'action stable: MANKIND n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de MANKIND ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1991 | 20,451 | Sheetal Arora | www.mankindpharma.com |
Mankind Pharma Limited développe, fabrique et commercialise des formulations pharmaceutiques et des produits de santé grand public, principalement en Inde et à l'étranger. L'entreprise développe des produits pharmaceutiques pour des traitements aigus et chroniques dans les domaines suivants : anti-infectieux, cardiovasculaire, gastro-intestinal, antidiabétique, dermatologie, douleur/analgésique, neuro/CNS, vitamines/minéraux/nutriments et maladies respiratoires. Elle fournit des produits de santé grand public, tels que des préservatifs, des kits de détection de grossesse, des contraceptifs d'urgence, des poudres antiacides, des suppléments de vitamines et de minéraux et des préparations anti-acnéiques.
Mankind Pharma Limited Résumé des fondamentaux
| MANKIND statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹1.03t |
| Bénéfices(TTM) | ₹20.43b |
| Recettes(TTM) | ₹147.38b |
50.2x
Ratio P/E7.0x
Ratio P/SLe site MANKIND est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MANKIND compte de résultat (TTM) | |
|---|---|
| Recettes | ₹147.38b |
| Coût des recettes | ₹43.09b |
| Marge brute | ₹104.29b |
| Autres dépenses | ₹83.86b |
| Les revenus | ₹20.43b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 49.46 |
| Marge brute | 70.76% |
| Marge bénéficiaire nette | 13.86% |
| Ratio dettes/capitaux propres | 38.1% |
Quelles ont été les performances à long terme de MANKIND?
Voir les performances historiques et les comparaisonsDividendes
0.08%
Rendement actuel des dividendesn/a
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/03 19:38 |
| Cours de l'action en fin de journée | 2026/08/03 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Mankind Pharma Limited est couverte par 37 analystes. 19 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |